About T-cell acute lymphocytic leukemia protein 1
T-cell acute lymphocytic leukemia protein 1 (TAL1) is a protein
from Homo sapiens identified by UniProt accession
P17542, 331 residues long.
MolForge cross-references it against 0 known binders and
461 disease associations.
Target properties
| Protein name | T-cell acute lymphocytic leukemia protein 1 |
| UniProt accession | P17542 |
| Gene | TAL1 |
| Organism | Homo sapiens |
| Length | 331 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (461)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.43
- mean corpuscular hemoglobin concentration · score 0.42
- mean corpuscular hemoglobin · score 0.41
- Red cell distribution width · score 0.39
- body mass index · score 0.38
- T-cell acute lymphoblastic leukemia · score 0.38
- Cutaneous T-cell lymphoma · score 0.37
- unspecified peripheral T-cell lymphoma · score 0.37
- T-lymphoblastic lymphoma · score 0.37
- mean platelet volume · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P17542-F1 | alphafold | PREDICTED | 60.38 | — |
Amino-acid sequence (331 residues)
MTERPPSEAA RSDPQLEGRD AAEASMAPPH LVLLNGVAKE TSRAAAAEPP VIELGARGGP GGGPAGGGGA ARDLKGRDAA TAEARHRVPT TELCRPPGPA PAPAPASVTA ELPGDGRMVQ LSPPALAAPA APGRALLYSL SQPLASLGSG FFGEPDAFPM FTTNNRVKRR PSPYEMEITD GPHTKVVRRI FTNSRERWRQ QNVNGAFAEL RKLIPTHPPD KKLSKNEILR LAMKYINFLA KLLNDQEEEG TQRAKTGKDP VVGAGGGGGG GGGGAPPDDL LQDVLSPNSS CGSSLDGAAS PDSYTEEPAP KHTARSLHPA MLPAADGAGP R
Explore T-cell acute lymphocytic leukemia protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets